Nachrichten zur BioCryst Pharmaceuticals Inc. Aktie

…

Key PointsBioCryst Pharmaceuticals (NASDAQ:BCRX) posted record GAAP revenue of $163.4 million in Q2 2025. and achieved its first significant GAAP…

BCRX gears up for Q2 results with Orladeyo growth in focus, but 2025 EPS forecasts dip as investors eye pipeline…

RESEARCH TRIANGLE PARK, N.C., July 31, 2025 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that its…

RESEARCH TRIANGLE PARK, N.C., July 21, 2025 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the…

Here is how BioCryst Pharmaceuticals (BCRX) and Cardinal Health (CAH) have performed compared to their sector so far this year.…

Does BioCryst Pharmaceuticals (BCRX) have what it takes to be a top stock pick for momentum investors? Lets find out.…

Does BioCryst Pharmaceuticals (BCRX) have what it takes to be a top stock pick for momentum investors? Lets find out.…

BioCryst Pharmaceuticals Inc. (BCRX) (i.) hat sich auf seltene Krankheiten spezialisiert. Das Hauptprodukt des Unternehmens ist ORLADEYO (Berotralstat), ein einmal…

BioCryst Pharmaceuticals Inc. (BCRX) (i.) hat am 05. Mai die Erwartungen der Experten mit den vorgelegten Zahlen für das 1.…

BioCryst (BCRX) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as…

Investors clearly werent in a forgiving mood on Monday when it came to BioCryst Pharmaceuticals (NASDAQ: BCRX) stock. After the…

BCRX earnings call for the period ending December 31, 2024.…

…

BioCryst (BCRX) doesnt possess the right combination of the two key ingredients for a likely earnings beat in its upcoming…

…

RESEARCH TRIANGLE PARK, N.C., Nov. 18, 2024 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the Health…

BCRX earnings call for the period ending September 30, 2024.…

…

…

…

RESEARCH TRIANGLE PARK, N.C., Sept. 06, 2024 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced the presentation of…

RESEARCH TRIANGLE PARK, N.C., Sept. 04, 2024 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that…

RESEARCH TRIANGLE PARK, N.C., Aug. 22, 2024 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the…

BCRX earnings call for the period ending June 30, 2024.…

…

RESEARCH TRIANGLE PARK, N.C., Aug. 02, 2024 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that…

RESEARCH TRIANGLE PARK, N.C., July 22, 2024 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the…

…

RESEARCH TRIANGLE PARK, N.C., July 02, 2024 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that…

RESEARCH TRIANGLE PARK, N.C., June 04, 2024 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that…

RESEARCH TRIANGLE PARK, N.C., May 13, 2024 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the…

BCRX earnings call for the period ending March 31, 2024.…

…

…

BioCryst (BCRX) delivered earnings and revenue surprises of 26.09% and 8.37%, respectively, for the quarter ended March 2024. Do the…

RESEARCH TRIANGLE PARK, N.C., April 17, 2024 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the…

BCRX earnings call for the period ending December 31, 2023.…

…